Long-term Follow-up of Gastrectomized Patients With Mucosa-associated Lymphoid Tissue Lymphoma
- 1 February 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 247 (2), 265-269
- https://doi.org/10.1097/sla.0b013e3181582364
Abstract
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by multifocality of the tumors, which often scatter over the mucosa of the stomach and adjacent upper gastrointestinal tract, and is therefore theoretically not curable by surgical resection. We conducted a long-term follow-up study of 14 patients who received surgical treatment for gastric MALT lymphoma. Tissues from the surgical margins of the resected stomach were analyzed by polymerase chain reaction-based amplification of the complementarity-determining region 3 of the IgH gene for the presence of residual tumors. T (11;18)(q21;q21), a marker of Helicobacter pylori-independent MALT lymphoma, was analyzed by reverse transcription polymerase chain reaction. All living patients were restaged, and rebiopsied if suspicious lesions were identified. At a median follow-up of 11.5 years, only 1 patient had evidence of tumor recurrence. Three patients with molecularly proven residual tumors in the surgical margin remained disease-free at 9.6 to 11.6 years. Five patients with t(11;18)(q21;q21) in the tumor cells were disease-free at 9.2 to 12.6 years. Our results indicate that surgical resection is a highly curative treatment for gastric MALT lymphoma, even for patients with residual tumor cells in the surgical margins, and for patients with H. pylori-independent tumors. A revisit of surgical treatment for gastric MALT lymphoma is mandatory.Keywords
This publication has 31 references indexed in Scilit:
- Molecular subtyping of gastric MALT lymphomas: implications for prognosis and managementGut, 2006
- Persistent Residual Disease in t(11;18)(q21;q21) Positive Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Treated With Chemotherapy or RituximabJournal of Clinical Oncology, 2005
- Long-Term Results of Anti– Helicobacter pylori Therapy in Early-Stage Gastric High-Grade Transformed MALT LymphomaJNCI Journal of the National Cancer Institute, 2005
- Prognostic Value of Translocation t(11;18) in Tumoral Response of Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue Type to Oral ChemotherapyJournal of Clinical Oncology, 2005
- Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori TherapyJournal of Clinical Oncology, 2005
- Gastrointestinal lymphoma: where morphology meets molecular biologyThe Journal of Pathology, 2005
- T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradicationGastroenterology, 2002
- Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapyThe Lancet, 2001
- Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.Journal of Clinical Oncology, 1998
- B‐CELL LYMPHOMA OF MALT TYPE: A REVIEW WITH SPECIAL EMPHASIS ON DIAGNOSTIC AND MANAGEMENT PROBLEMS OF LOW‐GRADE GASTRIC TUMOURSBritish Journal of Haematology, 1998